Navigation Links
Express Diagnostics Welcomes New Controller
Date:10/24/2013

Blue Earth, MN (PRWEB) October 24, 2013

Express Diagnostics Int’l, Inc. (EDI) is pleased to welcome Dave Klabunde as controller. In the position, Klabunde will direct EDI’s finance department, as well as serve an advisory role in company-wide financial and business decisions.

Klabunde previously served as financial analyst/controller for Fairmont Orthopedics & Sports Medicine and, prior to that, as program-operations manager at Youth Services International, Inc. (YSI), a residential treatment facility for juveniles. While at YSI, Klabunde was involved in all aspects of the organization’s operations, including operational planning and direction of cross-functional departments, financial planning, and leading human resources information systems and information technology initiatives.

“We are very pleased to have Dave join our team as controller,” says Paul Johnson, CEO of Express Diagnostics. “His extensive background in business and financial planning, as well as his broad operations experience, will be a great asset in clarifying decision points as we progress as a company. Dave will be instrumental in helping management direct our tremendous growth.”

Klabunde started with EDI in early October and looks forward to ‘getting up to speed’ with the various tasks and departments he will be involved with as controller. “I like the business side of controller duties, because numbers don’t lie,” he says. “My role will be to look forward and around what’s going on to allow management to make decisions on the overall direction of the organization.”

Originally from Nebraska, Klabunde has lived in the Blue Earth, Minn., area since 1997. He and his wife, Karen, have three children: Ryanne, 15; Taylor and Matthew, both 8.

About Express Diagnostics Int’l, Inc.

Express Diagnostics Int’l manufactures and distributes DrugCheck® on-site urine and saliva screening devices for the detection of drugs of abuse, as well as a growing catalog of rapid alcohol screening and health diagnostics devices. With accuracy comparable to laboratory testing, Express Diagnostics onsite devices provide a variety of industries fast, cost-effective alternatives to higher-priced lab services. Learn more at drugcheck.com.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11262425.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
3. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
4. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
5. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
6. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
7. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
8. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
9. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
10. transOMIC technologies Releases Tagged ORF Clones for Protein Expression
11. Free Research Report on Dyax Corp., Ebix, Inc., 8x8, Inc., EnerSys and Express Scripts Holding Co.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Massachusetts , February 4, 2016 - New FDA ... - New FDA action date of July 22, ... of July 22, 2016   - ... U.S. in the past decade indicated for the treatment of signs and symptoms ... Lifitegrast has the potential to be the only product approved in the U.S. ...
(Date:2/4/2016)... China , Feb. 4, 2016 Beike ... and various medical institutions attended a ceremony in late ... integrative, personalized cell therapy in 2016. ... "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" was ... Regional Cell Production Center, both subsidiaries of Beike Biotechnology ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ... "Emotion Detection and Recognition Market by ... Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020" report ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition of ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/2/2016)... Calif. , Feb. 2, 2016  Based ... market, Frost & Sullivan recognizes US-based Intelligent Retinal ... Frost & Sullivan Award for New Product Innovation. ... in North America , is ... the rapidly growing diabetic retinopathy market. The IRIS ...
Breaking Biology News(10 mins):